ClinicalTrials.gg
RecruitingNCT06536257PIP-PREDICTUpdated Oct 7, 2026

Personalised Immunotherapy Platform

An observational study in Melanoma, Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Melanoma Institute Australia. Recruiting at 3 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Melanoma Institute Australia · Observational

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Melanoma by Melanoma Institute Australia — 5 open to participants now, 9 under way, none of them phase 3. Melanoma · Melanoma Institute Australia.

Started
2021
with 1 other
Observational
Only one
of the 13
Registered
10th of 13
by date

Among the 13 studies in Melanoma by Melanoma Institute Australia, this one is one of 2 that started in 2021, is the only observational one, and was the 10th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

5 of the 13 studies in Melanoma by Melanoma Institute Australia are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Melanoma by Melanoma Institute Australia, or all of them as a file.
02

Study summary

This is a non-interventional study to prospectively test a suite of predictive biomarker models of immunotherapy resistance in patients with melanoma, non-melanoma skin cancers and other solid tumours. The study will evaluate the documentation, processes, accuracy and utility of the predictive biomarker model in clinical practice.

Read the detailed description

The Personalised Immunotherapy Program (PIP) is a multicenter biomarker discovery and validation program of multi-omic biomarker based predictive models which aim to identify patients with immunotherapy resistant disease. PIP developed predictive models in retrospective setting, with validation within a prospective clinical observational study.

Immune checkpoint inhibitors targeting the cytotoxic T-cell lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) receptors have revolutionised the treatment of advanced melanoma, resulting in long-term durable responses and a 5-year overall survival of 52% with combination immunotherapy. However, clinical benefit is not universal, and half of these patients do not respond. Therefore, there is an urgent need for clinically validated biomarkers which can identify patients who are at high risk of not responding to standard-of-care immunotherapies and determine which emerging clinical trial agent is most appropriate for a particular patient's disease.

Researchers performed mutation, gene expression and tumour immune profiling on tumour biopsies from melanoma patients treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy. From this dataset PIP has developed predictive models to identify patients with immunotherapy resistant disease.

The subsequent PIP-PREDICT is a prospective clinical study that enrols advanced cancer patients who are eligible to receive approved immunotherapies. PIP testing and biomarker reporting is used to screen potential patients. Each patient enrolled in the study receives an individual PIP Biomarker Report, which is presented as part of the established Biomarker Multidisciplinary Team (MDT) meeting of clinical oncologists, pathologists, molecular biologists, trials nursing, PIP, and biospecimen staff on a fortnightly basis.

PIP-PREDICT has a primary goal of determining the accuracy of biomarker predictions from PIP prospectively within oncology clinics. Secondary goals include assessing the feasibility of biomarker assay workflows within diagnostic providers, conducting a cost-benefit ratio analysis, evaluating the effect of biomarker reports on treatment selection within multidisciplinary teams (MDTs), and performing a post-implementation analysis of personalised immunotherapy biomarker reports in treatment decision making.

03

Conditions studied

  • Melanoma
  • Cutaneous Squamous Cell Carcinoma
  • Basal Cell Carcinoma
  • Merkel Cell Carcinoma
  • Solid Tumor

Keywords

  • Biomarker
  • Predictive
  • Immunotherapy
  • Multi-omic
  • Tumour mutation burden
  • Gene expression
  • Tissue imaging
  • Machine learning
  • Multiplex immunofluorescence
  • Immune checkpoint inhibitors
  • Quantitative pathology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with melanoma, non-melanoma skin cancer, non-melanoma solid tumours eligible for treatment with immunotherapy(ies)

Eligibility criteria

MELANOMA:

Inclusion Criteria:

  1. Written to participation for the use of tumour tissue, blood and stool and collection of standard clinical data.
  2. confirmed resected stage II (at high risk of recurrence of disease), III or stage IV melanoma (including cutaneous, mucosal, acral, subungual, uveal or unknown primary melanoma) and unresectable Stage III or IV melanoma
  3. Eligible to receive immunotherapy
  4. Availability of a melanoma tissue sample which was obtained at surgery and where no systemic treatments (e.g. treatment) were administered between sample procurement and proposed PIP testing
  5. Patients who have received adjuvant or neoadjuvant systemic therapy in the past are eligible if they have had recurrence after neoadjuvant or adjuvant therapy has been completed and the represents this disease
  6. version 1.1 .
  7. Tissue sample must be representative of the whole tumour and therefore excision biopsies are preferred over core biopsies.
  8. A over 6 months.
  9. Prior treatment with BRAF (B-Raf proto-oncogene) / MEK (mitogen-activated protein kinase) inhibitors are acceptable, providing the other eligibility criteria are met.
  10. If a patient has had prior radiotherapy for melanoma, the biopsy to be used for the biomarker test must be from an area that was not within the radiotherapy field.

Exclusion Criteria:

1. Patients will be excluded if they have had a positive test result for virus surface antigen (HBV sAg) or virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. If receiving treatment and from HCV for at least one year, patients are allowed to participate. No new testing is required for the sole purpose of this pilot phase. Patients will be excluded if they have known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS). No new testing is required

NON-MELANOMA:

Inclusion Criteria:

  1. Written informed consent to participation for the use of tumour tissue and collection of standard clinical data
  2. Histologically confirmed cancer and eligibility to receive immunotherapy treatment.
  3. Availability of a tissue sample where no systemic treatments were administered between sample procurement and proposed PIP testing
  4. If treatment has been administered since the last tissue sample was obtained, a new biopsy should be planned for routine testing or clinical trial screening, where a portion of the sample can be used for the predictive assay. No new biopsies are required for the sole purpose of this study.
  5. Patients who have received adjuvant or neoadjuvant systemic therapy in the past are eligible if they have had recurrence after neoadjuvant or adjuvant therapy has been completed and the biopsy represents this relapsed disease.
  6. Have clinically detectable disease defined as one of more of the following:

    • RECIST measurable. Lesions situated in a previously irradiated area are considered measurable if RECIST-defined disease progression since radiotherapy has been demonstrated in such lesions, OR,
    • Positron Emission Tomography (PET) avid, OR,
    • Clinically evident disease: photographically, detectable on CT or palpable, OR
    • Clinical status measured by observable and diagnosable signs or symptoms.
  7. The tissue sample must be representative of the whole tumour and therefore excision biopsies are preferred over core biopsies.
  8. A life expectancy over 6 months.
  9. Prior treatment with targeted therapies are acceptable, providing the other eligibility criteria are met.
  10. If a patient has had prior radiotherapy for melanoma, the biopsy to be used for the biomarker test must be from an area that was not within the radiotherapy field

Exclusion Criteria:

1. Patients will be excluded if they have had a positive test result for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody), indicating acute or chronic infection. If receiving treatment and from HCV for at least one year, patients are allowed to participate. No new testing is required for the sole purpose of this pilot phase. Patients will be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS). No new testing is required

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Melanoma cohort

    Patients with melanoma who are yet to receive immunotherapy will undergo predictive biomarker testing and biomarker reporting.

    Other: Predictive model

  • Non-melanoma skin cancer cohort

    Patients with non-melanoma skin cancers (basal cell carcinoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma) who are yet to receive immunotherapy will have tumour tested using the predictive model.

    Other: Predictive model

  • Solid tumour cohort

    Patients with non-melanoma, non-skin cancer, solid tumours who are yet to receive immunotherapy will have tumour tested using the predictive model.

    Other: Predictive model

Interventions

  • OtherPredictive model

    Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.

06

What researchers measure

Primary outcomes

  1. Assessment of the accuracy of predictive test results in melanoma

    Proportion of correctly predicted responders and non-responders to the immunotherapy treatment decision by the MDT, based on the 6 month progression-free survival (PFS)

    Time frame: 6 months

Secondary outcomes

  1. Assessment of the inaccuracy of predictive test results

    Identification of patient populations for which the predictive model did not predict response (6 month PFS) to immunotherapy

    Time frame: 6 months

  2. Evaluation of a test request form - completion rate

    Proportion of required data completed by the referring clinician

    Time frame: 2 years

  3. Analysis of potential barriers to complete a test request form

    Identification of barriers to completion of the request form

    Time frame: 2 years

  4. Evaluation of accessible data in medical records for completion of a test request form

    Proportion of required data that is readily available in routine patient medical records

    Time frame: 2 years

  5. Evaluation of a test request form from clinician feedback via qualitative surveys

    Summarised feedback from clinicians in narrative format

    Time frame: 2 years

  6. Conduct qualitative surveys to evaluate a test result report from consumers' viewpoint

    Survey results from consumer responses on the comprehension of risk probability (mean score from a 7 point scale), communication efficacy (mean score from a 4 point scale), significance and actionability (mean score from a 7 point scale) of the information within the report

    Time frame: 1 year

  7. Qualiaitive evaluation of a test result report from consumers' viewpoint

    Interviewer notes and transcriptions of consumers' answers to structured interview questions coded in software for qualitative data to identify and evaluate the most significant problems, highlight cases of poor comprehension, and assess the degree to which the reports met consumers' information needs

    Time frame: 1 year

  8. Conduct qualitative surveys to evaluation of a test result report from the clinicians' viewpoint

    Survey results from clinicians on the utility (mean score from a 7 point scale) and comprehension (mean score from a 7 point scale) of the report

    Time frame: 2 years

  9. Qualiaitive evaluation of a test result report from clinicians' viewpoint

    Summarised feedback from clinicians to structured interview questions

    Time frame: 2 years

  10. Evaluation of the predictive model workflow on result completion

    Identification of workflow barriers from request form to result delivery

    Time frame: 2 years

  11. Evaluation of the predictive model workflow on result delivery

    Time from request form submission to predictive test result delivery (business days)

    Time frame: 2 years

  12. Evaluation of the predictive model workflow turnaround timeframes

    Proportion of test results received within 2 weeks (10 business days) from request

    Time frame: 2 years

  13. Evaluation of the predictive model workflow delays

    Summary of reasons for delay in providing test result

    Time frame: 2 years

  14. Evaluation of the predictive model workflow processes

    Identification of processes that require change (if required), the number of identified issues found and the result of implemented changes.

    Time frame: 2 years

  15. Availability of suitable tissue for the predictive model testing protocol

    Proportion of patients who could not be tested because no suitable tissue available (and reasons why).

    Time frame: 2 years

  16. Data quality for the predictive model testing protocol

    Proportion of patients who could not be tested because of missing clinical data (and which data and why missing)

    Time frame: 2 years

  17. A cost analysis of the predictive model testing protocol

    Calculation of the cost per individual test (to include staff time, reagents, proportionate use of analytical equipment, assay costs, pathology service fee for sample preparation and shipping)

    Time frame: 2 years

  18. Evaluation of the predictive test report in shaping clinician treatment decision making

    Index of the quality of team decision making using the multidisciplinary team (MDT) metric of decision making (MODe) framework

    Time frame: 1 year

  19. Evaluation of the impact of predictive test result in shaping clinician treatment decision making

    Decision making with and without the knowledge of the predictive test report (Decision Impact Analysis) by the MDT

    Time frame: 2 years

  20. Concordance of clinician treatment decision making with predictive test results

    Concordance of treatment recommendation(s) before and after provision of the predictive test report per patient case

    Time frame: 2 years

  21. Discordance of clinician treatment decision making with predictive test results

    For treatment choice discordance, proportion of theoretical decisions based on the report that would be adhered to

    Time frame: 2 years

  22. Exploratory evaluation of potential new biomarkers of immunotherapy response or resistance in blood and stool samples

    Identification of biomarkers in blood and/or stools predictive of response or resistance to immunotherapy that can be incorporated into the predictive model

    Time frame: 5 years

  23. Evaluation of potential new biomarkers of immunotherapy response or resistance in blood and stool samples on the accuracy of the predictive model

    Impact of the inclusion of blood and/or stool biomarkers to the accuracy of the predictive model on predicting response to immunotherapy at 6 months post-treatment

    Time frame: 5 years

  24. Assessment of the accuracy of predictive test results in non-melanoma skin cancer and non-melanoma tumours

    Proportion of correctly predicted responders and non-responders to immunotherapy treatment based on the 6 month progression-free survival

    Time frame: 6 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Gide TN, Paver EC, Yaseen Z, Maher N, Adegoke N, Menzies AM, Pires da Silva I, Wilmott JS, Long GV, Scolyer RA. Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies. Oncoimmunology. 2023 Oct 4;12(1):2261248. doi: 10.1080/2162402X.2023.2261248. eCollection 2023. PubMed 37808404 ↗
  • Mao Y, Gide TN, Adegoke NA, Quek C, Maher N, Potter A, Patrick E, Saw RPM, Thompson JF, Spillane AJ, Shannon KF, Carlino MS, Lo SN, Menzies AM, da Silva IP, Long GV, Scolyer RA, Wilmott JS. Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach. J Transl Med. 2023 Apr 13;21(1):257. doi: 10.1186/s12967-023-04092-9. PubMed 37055772 ↗
  • Adegoke NA, Gide TN, Mao Y, Quek C, Patrick E, Carlino MS, Lo SN, Menzies AM, Pires da Silva I, Vergara IA, Long G, Scolyer RA, Wilmott JS. Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. J Immunother Cancer. 2023 Oct;11(10):e007144. doi: 10.1136/jitc-2023-007144. PubMed 37865395 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.

Of 177 non-industry observational studies under Melanoma, half reached primary completion within 178 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 320. This study's planned 71 months is below that.

Counting every sponsor, half of 236 studies reached it within 71 months; a quarter within 35 and three quarters within 248.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2024
First posted
Aug 2, 2024
StartActual
Jun 8, 2021
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2037
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06536257
Lead sponsor
Melanoma Institute Australia
Responsible party
Sponsor
First posted
Aug 2, 2024
Start date
Jun 8, 2021
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2037 (estimated)
Last update
Oct 7, 2026

Study contacts

Personalised Immunotherapy Program Manager
Contact
PIP@melanoma.org.au
+61 2 9911 7200
James Wilmott, PhD
principal investigator · Melanoma Institute Australia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion